Renal & Urology News reports testosterone therapy was associated with adverse cardiovascular (CV) outcomes in a large observational study. The findings raise questions about the potential safety of testosterone use in men.
Of the 8,709 study subjects with low testosterone, 1,223 (14%) started testosterone therapy after a median of 531 days following coronary angiography. Those patients tended to be younger (mean age 61 years) than the testosterone non-users (mean age 64 years) and tended to have lower rates of congestive heart failure, renal failure, and other comorbidities.
Approximately one of every five men not taking testosterone died and/or had a heart attack or a stroke, compared with approximately one out of four testosterone users. Testosterone therapy was associated with a 29% greater risk of these events.
The investigators emphasized the need for more research, including randomized controlled trials, to properly characterize the risks of testosterone therapy in men with comorbidities.
If you or a loved one have suffered a stroke or heart attack after undergoing testosterone replacement therapy, including taking AndroGel, Axiron, Fortesta, Testim, or Androderm, please call our office for a free consultation from one of our experienced product liability attorneys regarding a potential lawsuit.